These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
313 related articles for article (PubMed ID: 28431669)
1. After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists? Vergès B; Charbonnel B Diabetes Metab; 2017 Apr; 43 Suppl 1():2S3-2S12. PubMed ID: 28431669 [TBL] [Abstract][Full Text] [Related]
2. Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review. Boyle JG; Livingstone R; Petrie JR Clin Sci (Lond); 2018 Aug; 132(15):1699-1709. PubMed ID: 30115742 [TBL] [Abstract][Full Text] [Related]
4. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797 [TBL] [Abstract][Full Text] [Related]
5. Cardiovascular safety and benefits of GLP-1 receptor agonists. Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093 [TBL] [Abstract][Full Text] [Related]
6. Effects of glucagon-like peptide-1 receptor agonists on mortality and cardiovascular events: A comprehensive meta-analysis of randomized controlled trials. Monami M; Zannoni S; Pala L; Silverii A; Andreozzi F; Sesti G; Mannucci E Int J Cardiol; 2017 Aug; 240():414-421. PubMed ID: 28501352 [TBL] [Abstract][Full Text] [Related]
8. Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials. Verma S; McGuire DK; Bain SC; Bhatt DL; Leiter LA; Mazer CD; Monk Fries T; Pratley RE; Rasmussen S; Vrazic H; Zinman B; Buse JB Diabetes Obes Metab; 2020 Dec; 22(12):2487-2492. PubMed ID: 32744418 [TBL] [Abstract][Full Text] [Related]
9. [Cardiovascular effects of GLP-1 receptor agonist treatment: focus on liraglutide]. Haluzík M; Trachta P; Mráz M Vnitr Lek; 2015; 61(7-8):635-40. PubMed ID: 26375689 [TBL] [Abstract][Full Text] [Related]
10. Assessment of Cardiovascular Risk With Glucagon-Like Peptide 1 Receptor Agonists in Patients With Type 2 Diabetes Using an Alternative Measure to the Hazard Ratio. Kaneko M; Narukawa M Ann Pharmacother; 2018 Jul; 52(7):632-638. PubMed ID: 29424239 [TBL] [Abstract][Full Text] [Related]
11. Update in Cardiovascular Safety of Glucagon Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes. A Mixed Treatment Comparison Meta-Analysis of Randomised Controlled Trials. Al Yami MS; Alfayez OM; Alsheikh R Heart Lung Circ; 2018 Nov; 27(11):1301-1309. PubMed ID: 29887418 [TBL] [Abstract][Full Text] [Related]
12. Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns. Lim S; Kim KM; Nauck MA Trends Endocrinol Metab; 2018 Apr; 29(4):238-248. PubMed ID: 29463450 [TBL] [Abstract][Full Text] [Related]
13. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system. Vergès B; Bonnard C; Renard E Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831 [TBL] [Abstract][Full Text] [Related]
14. GLP-1R as a Target for the Treatment of Diabetic Retinopathy: Friend or Foe? Simó R; Hernández C Diabetes; 2017 Jun; 66(6):1453-1460. PubMed ID: 28533296 [TBL] [Abstract][Full Text] [Related]
16. [Results of the LEADER study: current evidence and perspectives in research]. Mannucci E G Ital Cardiol (Rome); 2016 Dec; 17(12 Suppl 2):28S-31. PubMed ID: 28151519 [TBL] [Abstract][Full Text] [Related]
17. Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study. Morano S; Romagnoli E; Filardi T; Nieddu L; Mandosi E; Fallarino M; Turinese I; Dagostino MP; Lenzi A; Carnevale V Acta Diabetol; 2015 Aug; 52(4):727-32. PubMed ID: 25577244 [TBL] [Abstract][Full Text] [Related]
18. Cardiovascular risk profiles: A cross-sectional study evaluating the generalizability of the glucagon-like peptide-1 receptor agonist cardiovascular outcome trials REWIND, LEADER and SUSTAIN-6 to the real-world type 2 diabetes population in the United Kingdom. Webb J; Mount J; von Arx LB; Rachman J; Spanopoulos D; Wood R; Tritton T; Massey O; Idris I Diabetes Obes Metab; 2022 Feb; 24(2):289-295. PubMed ID: 34668637 [TBL] [Abstract][Full Text] [Related]
19. Glucagon-like peptide 1 receptor agonists and cardiovascular risk in type 2 diabetes: a clinical perspective. Fisher M Diabetes Obes Metab; 2015 Apr; 17(4):335-42. PubMed ID: 25155010 [TBL] [Abstract][Full Text] [Related]
20. Pleiotropic effects of insulin and GLP-1 receptor agonists: Potential benefits of the association. Cariou B Diabetes Metab; 2015 Dec; 41(6 Suppl 1):6S28-6S35. PubMed ID: 26774017 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]